2010
Docetaxel
Phillips C, Petrylak D. Docetaxel. 2010, 133-146. DOI: 10.1007/978-1-60327-829-4_12.Peer-Reviewed Original ResearchCastration-resistant prostate cancerAndrogen deprivation therapyProstate-specific antigenProstate cancerInitial androgen deprivation therapyFirst treatment regimenSecondary hormonal manipulationsStandard chemotherapy combinationTaxane combination therapyFirst-line treatmentUse of docetaxelProstate cancer screeningDeprivation therapyRecurrent diseaseChemotherapy combinationsDocetaxel therapyPSA responseTreatment regimenTreatment optionsCancer screeningDisease progressionHormonal manipulationBetter survivalInvestigational usesSurgical castration
1992
Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer
Seidman A, Scher H, Petrylak D, Dershaw D, Curley T. Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer. Journal Of Urology 1992, 147: 931-934. PMID: 1371564, DOI: 10.1016/s0022-5347(17)37426-8.Peer-Reviewed Original ResearchConceptsHormone-refractory prostatic cancerProstatic cancerProgressive hormone-refractory prostate cancerElevated prostate-specific antigen levelsProstate-specific antigen levelHormone-refractory prostate cancerClinical trial end pointsOutpatient treatment regimenRefractory prostate cancerSpecific antigen levelsTrial end pointsProstate-specific antigenManageable toxicityMedian durationPartial responsePSA levelsTreatment regimenEstramustine phosphateAntigen levelsProstate cancerAdditive cytotoxicityMedian decreasePatientsSpecific antigenHuman prostate